165P Trabectedin or gemcitabine-based chemotherapy as second-line therapy for advanced leiomyosarcoma: An IPTW-adjusted analysis

ESMO rare cancers. 2026 Open access

Read full text
Authors: S. Garofalo, Maria Chiara Sergi, Sarah V Williams, C. Benson, Emine Hatipoglu, R.L. Jones, A. Napolitano
DOI: 10.1016/j.esmorc.2026.100371
Cited by: 0

Abstract

Leiomyosarcoma (LMS) is an aggressive mesenchymal malignancy accounting for 10–20% of soft tissue sarcomas. After progression on anthracycline-based therapy, treatment options are limited and no standard second-line regimen exists. Trabectedin (T) and gemcitabine-based (G) chemotherapy are widely used, but treatment allocation may be influenced by prognostic factors, introducing selection bias. The aim of this study is to compare outcomes of patients treated with T and G in second line.

Fields of Study & Subjects

Sarcoma Diagnosis and Treatment Acute Myeloid Leukemia Research Gastrointestinal Tumor Research and Treatment

Publication details

Journal / source
ESMO rare cancers.
Volume
5
Pages
100371–100371
Publication date
1 March 2026
Language
EN